RxSight (RXST) Wells Fargo 21st Annual Healthcare Conference summary

Business performance and strategic priorities

• Focus is on growing the U.S. business, advancing the product pipeline, and leveraging the Alcon partnership to transform the cataract surgery market.

• Commercial strategy is shifting from initial adoption to driving deeper utilization among existing users, with a plan to double the U.S. sales force for more frequent and targeted engagement.

• Emphasis on education, practice integration, and peer-to-peer sharing to overcome perceived barriers such as chair time and cost, aiming to expand the patient base beyond post-refractive cases.

• Management is prioritizing disciplined capital allocation and operational rigor to improve efficiency and maintain strong gross margins in the mid-70% range.

• International expansion is considered a secondary priority, with primary efforts focused on reestablishing U.S. growth before scaling globally.

Market dynamics and competition

• The adjustable lens segment is positioned as distinct from other premium intraocular lenses, with a focus on unique outcomes and tailorability.

• Competitive pressures are acknowledged, but management believes new entrants offer only incremental innovation, and plans to insulate the business by emphasizing differentiation.

• The Alcon collaboration is seen as a transformative long-term opportunity, providing significant upfront capital and a 30% royalty, with potential to access over 50% of the premium cataract surgery market.

• Management is developing a robust strategy to address competition, market education, and utilization depth, with formal guidance expected in early 2027.

• Pipeline development and the Alcon partnership are expected to expand the patient population and streamline outcomes, with timelines for new products to be announced as development progresses.

Financial outlook and operational execution

• The business is currently flat to declining but aims to return to growth by 2027 through a focused commercial overhaul and execution of the new strategy.

• Management expects some choppiness in early 2027 due to seasonality and transition, but anticipates improved trajectory as the year progresses.

• Resource reallocation and expense discipline are central to funding commercial investments without significant increases in operating expenses.

• The company maintains a strong balance sheet with over $210 million in cash and $60 million from the Alcon deal, targeting break-even in the future.

• Long-term vision is to be recognized as a disciplined, high-growth company with durable revenue streams and strong market impact.